{
  "url": "https://www.benzinga.com/quote/VOR/report",
  "authorsByline": "",
  "articleId": "a820596950854176960bf8dbad635da4",
  "source": {
    "domain": "benzinga.com",
    "paywall": false,
    "location": {
      "country": "us",
      "state": "MI",
      "county": "Wayne County",
      "city": "Detroit",
      "coordinates": {
        "lat": 42.3315509,
        "lon": -83.0466403
      }
    }
  },
  "imageUrl": "",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-23T20:49:34+00:00",
  "addDate": "2025-08-23T21:49:46.100046+00:00",
  "refreshDate": "2025-08-23T21:49:46.100047+00:00",
  "score": 1.0,
  "title": "Vor Biopharma (VOR) Stock Analysis Report",
  "description": "Explore Vor Biopharma (VOR) stock analysis with comprehensive data: access historical performance, financials, and insights. Updated August 2025",
  "content": "We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health. The chart below shows how we grade Vor Biopharma ( VOR ) across the board compared to its closest peers.\n\nOur estimate of future price growth is based on an aggregation of 3 analyst ratings over the past 3 months and their 12-month price targets. Below, you can see that analysts are estimating a 12-month price target range of $0.40 - $3.00 with an average of $1.85 Expected movement for Vor Biopharma ( VOR ) over the next 12 months\n\nHow has Vor Biopharma ( VOR ) performed over the past 5 years? The two main factors that we consider when analyzing past performance is overall return and volatility Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years. This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe. Vor Biopharma ( VOR ) sharpe ratio over the past 5 years is -0.1642 which is considered to be above average compared to the peer average of -0.3372",
  "medium": "Article",
  "links": [],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Vor Biopharma",
      "weight": 0.119451776
    },
    {
      "name": "past performance",
      "weight": 0.1165223
    },
    {
      "name": "future price growth",
      "weight": 0.105434716
    },
    {
      "name": "overall return",
      "weight": 0.09782915
    },
    {
      "name": "VOR",
      "weight": 0.09189816
    },
    {
      "name": "enough return",
      "weight": 0.08762676
    },
    {
      "name": "risk",
      "weight": 0.084128805
    },
    {
      "name": "overall financial health",
      "weight": 0.08311219
    },
    {
      "name": "return",
      "weight": 0.076776415
    },
    {
      "name": "stocks",
      "weight": 0.076774605
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.97607421875
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.970703125
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.96533203125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.833984375
    }
  ],
  "sentiment": {
    "positive": 0.32903385,
    "negative": 0.07820965,
    "neutral": 0.5927565
  },
  "summary": "We grade stocks based on their past performance, future growth potential, intrinsic value, dividend history, and financial health. Our analysis is based on an aggregation of 3 analyst ratings over the past three months and their 12-month price targets. The sharpe ratio, which is a measure of risk/reward trade-off for investors, is considered above average over the peer average of -0.3372. The company's current price target is $0.40 - $3.00.",
  "shortSummary": "Vor Biopharma's past performance compared to its closest peers is based on past returns, intrinsic value, and volatility, with potential for future price changes.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "17f751dbd2c849b5a22169770a4d0ac9",
  "places": [],
  "scraped_sources": [],
  "argos_summary": "The article evaluates Vor Biopharma (VOR) using a grading system that considers past performance, growth potential, intrinsic value, dividends, and financial health. Analysts project a 12\u2011month price target range of $0.40 to $3.00, averaging $1.85, indicating expected price movement. Over the past five years, VOR\u2019s Sharpe ratio of \u20130.1642 is better than the peer average of \u20130.3372, suggesting a relatively favorable risk\u2011reward profile.",
  "argos_id": "M2PF568NP"
}